The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients
Open accessAbstract
BACKGROUND: Quantification of disease-associated proteins in the cerebrospinal fluid (CSF) has been critical for the study and treatment of several neurodegenerative disorders; however, mutant huntingtin protein (mHTT), the cause of Huntington's disease (HD), is at very low levels in CSF and, to our knowledge, has never been measured previously. METHODS: We developed an ultrasensitive single-molecule counting (SMC) mHTT immunoassay that was used to quantify mHTT levels in CSF samples from individuals bearing the HD mutation and from control individuals in 2 independent cohorts. RESULTS: This SMC mHTT immunoassay demonstrated high specificity for mHTT, high sensitivity with a femtomolar detection threshold, and a broad dynamic range. Analysis of the CSF samples showed that mHTT was undetectable in CSF from all controls but quantifiable in nearly all mutation carriers. The mHTT concentration in CSF was approximately 3-fold higher in patients with manifest HD than in premanifest mutation carriers. Moreover, mHTT levels increased as the disease progressed and were associated with 5-year onset probability. The mHTT concentration independently predicted cognitive and motor dysfunction. Furthermore, the level of mHTT was associated with the concentrations of tau and neurofilament light chain in the CSF, suggesting a neuronal origin for the detected mHTT. CONCLUSIONS: We have demonstrated that mHTT can be quantified in CSF from HD patients using the described SMC mHTT immunoassay. Moreover, the level of mHTT detected is associated with proximity to disease onset and diminished cognitive and motor function. The ability to quantify CSF mHTT will facilitate the study of HD, and mHTT quantification could potentially serve as a biomarker for the development and testing of experimental mHTT-lowering therapies for HD. TRIAL REGISTRATION: Not applicable. FUNDING: CHDI Foundation Inc.; Medical Research Council (MRC) UK; National Institutes for Health Research (NIHR); Rosetrees Trust; Swedish Research Council; and Knut and Alice Wallenberg Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Adams, J. L., Dinesh, K., Xiong, M., Tarolli, C. G., Sharma, S., Sheth, N., Aranyosi, A. J., Zhu, W., Goldenthal, S., Biglan, K. M., et al. (2017) · Digital Biomarkers · doi:10.1159/000479018 · Cited by 3,171
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationHuntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743
Self-citationHuntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016
Self-citationTabrizi, S. J., Scahill, R. I., Owen, G., Durr, A., Leavitt, B. R., Roos, R. A., Borowsky, B., Landwehrmeyer, B., Frost, C., Johnson, H., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70088-7 · Cited by 846
Self-citationLangbehn, D., Brinkman, R., Falush, D., Paulsen, J., Hayden, M., & on behalf of an International Huntington's Disease Collaborative Group (2004) · Clinical Genetics · doi:10.1111/j.1399-0004.2004.00241.x · Cited by 817
Self-citationThe U.S.–Venezuela Collaborative Research Project*, & Wexler, N. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308679101 · Cited by 761
CAG repeat number governs the development rate of pathology in Huntington's disease
Penney, J. B., Vonsattel, J., Macdonald, M. E., Gusella, J. F., & Myers, R. H. (1997) · Annals of Neurology · doi:10.1002/ana.410410521 · Cited by 669
Björkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C. L., Soulet, D., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080178 · Cited by 650
Self-citationMiller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Rosengren, L. E., Karlsson, J., Karlsson, J., Persson, L. I., & Wikkelsø, C. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67052013.x · Cited by 499
Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm
Telenius, H., Kremer, B., Goldberg, Y. P., Theilmann, J., Andrew, S. E., Zeisler, J., Adam, S., Greenberg, C., Ives, E. J., Clarke, L. A., et al. (1994) · Nature Genetics · doi:10.1038/ng0494-409 · Cited by 439
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
Shi, M., Bradner, J., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Kim, H. M., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22311 · Cited by 418
Kennedy, L. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg352 · Cited by 380
Amyloid‐beta oligomerization in Alzheimer dementia versus high‐pathology controls
Esparza, T. J., Zhao, H., Cirrito, J. R., Cairns, N. J., Bateman, R. J., Holtzman, D. M., & Brody, D. L. (2013) · Annals of Neurology · doi:10.1002/ana.23748 · Cited by 306
Li, H., Li, S.-H., Johnston, H., Shelbourne, P. F., & Li, X.-J. (2000) · Nature Genetics · doi:10.1038/78054 · Cited by 303
Ultrasensitive Flow-based Immunoassays Using Single-Molecule Counting
Todd, J., Freese, B., Lu, A., Held, D., Morey, J., Livingston, R., & Goix, P. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.091181 · Cited by 289
Dalrymple, A., Wild, E. J., Joubert, R., Sathasivam, K., Björkqvist, M., Petersén, Å., Jackson, G. S., Isaacs, J. D., Kristiansen, M., Bates, G. P., et al. (2007) · Journal of Proteome Research · doi:10.1021/pr0700753 · Cited by 228
Self-citationKennedy, L. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.17.2539 · Cited by 199
Ko, J., Ou, S., & Patterson, P. H. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00599-8 · Cited by 191
A Sensitive Aβ Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid
Savage, M. J., Kalinina, J., Wolfe, A., Tugusheva, K., Korn, R., Cash-Mason, T., Maxwell, J. W., Hatcher, N. G., Haugabook, S. J., Wu, G., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1675-13.2014 · Cited by 183
Wang, C.-E., Tydlacka, S., Orr, A. L., Yang, S.-H., Graham, R. K., Hayden, M. R., Li, S., Chan, A. W. S., & Li, X.-J. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn175 · Cited by 163
Lewczuk, P., Beck, G., Esselmann, H., Bruckmoser, R., Zimmermann, R., Fiszer, M., Bibl, M., Maler, J. M., Kornhuber, J., & Wiltfang, J. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.058776 · Cited by 162
Targets for future clinical trials in Huntington's disease: What's in the pipeline?
Wild, E. J., & Tabrizi, S. J. (2014) · Movement Disorders · doi:10.1002/mds.26007 · Cited by 146
Self-citationMutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression
Weiss, A., Träger, U., Wild, E. J., Grueninger, S., Farmer, R. E., Landles, C., Scahill, R. I., Lahiri, N., Salman, H., Macdonald, D., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64565 · Cited by 143
Self-citationWeiss, A., Abramowski, D., Bibel, M., Bodner, R. A., Chopra, V., DiFiglia, M., Fox, J. H., Kegel, K. B., Klein, C., Grueninger, S., et al. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.08.001 · Cited by 126
Self-citationBaldo, B., Paganetti, P., Grueninger, S., Marcellin, D., Kaltenbach, L. S., Lo, D. C., Semmelroth, M., Zivanovic, A., Abramowski, D., Smith, D. L., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.020 · Cited by 78
Self-citationQuantification Assays for Total and Polyglutamine-Expanded Huntingtin Proteins
Macdonald, D., Tessari, M. A., Boogaard, I., Smith, M. W., Pulli, K., Szynol, A., Albertus, F., Lamers, M. B. A. C., Dijkstra, S., Kordt, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096854 · Cited by 73
Self-citationConstantinescu, R., Romer, M., Oakes, D., Rosengren, L., & Kieburtz, K. D. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.05.012 · Cited by 61
Belbin, O., Gomez‐Giro, G., Muñoz, L., Alcolea, D. A., Colom‐Cadena, M., Carmona‐Iragui, M., Fortea, J., Clarimón, J., Bayés, À., & Lleó, A. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.796 · Cited by 1
Cited by
Huntington's disease: a clinical review
McColgan, P., & Tabrizi, S. J. (2018) · European Journal of Neurology · doi:10.1111/ene.13413 · Cited by 1,089
Self-citationBridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764
Self-citationHuntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
Self-citationByrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30124-2 · Cited by 364
Self-citationHuntingtin Lowering Strategies for Disease Modification in Huntington’s Disease
Tabrizi, S. J., Ghosh, R., & Leavitt, B. R. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.039 · Cited by 337
Self-citation
Metadata
- Authors
- Wild, E. J., Boggio, R., Langbehn, D., Robertson, N., Haider, S., Miller, J. R. C., Zetterberg, H., Leavitt, B. R., Kuhn, R., Tabrizi, S. J., Macdonald, D., & Weiss, A.
- Venue
- Journal of Clinical Investigation
- Published
- 2015-04-06
- Volume
- 125
- Issue
- 5
- Pages
- 1979-1986
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2076843567
- Cited by
- 268
- References
- 34
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.